Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 Subunit

11 Jan 2021

Abstract excerpt

A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), caused a worldwide pandemic. Our aim in this study is to produce new fusion inhibitors against SARS-CoV-2, which can be the basis for developing new antiviral drugs. The fusion core comprising the heptad repeat domains (HR1 and HR2) of SARS-CoV-2 spike (S) were used to design the peptides. A total of twelve peptides were generated,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimicrobial Peptides and Activities
Share to SARS-CoV-2 and COVID-19 Research
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33424013
DOI: 10.4062/biomolther.2020.201

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 SubunitPMID 33424013Read ↗

Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the pre-hairpin intermediate of the spike proteinSemantic proximity Read ↗

Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusionSemantic proximity Read ↗

A macrocyclic peptide-based fusion inhibitor targeting SARS-CoV-2 Spike S2 subunitSemantic proximity Read ↗

Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptidesSemantic proximity Read ↗

Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccinesSemantic proximity Read ↗

Targeting an evolutionarily conserved “E-L-L” motif in the spike protein to develop a small molecule fusion inhibitor against SARS-CoV-2Semantic proximity Read ↗

A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of ConcernSemantic proximity Read ↗

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigenSemantic proximity Read ↗

Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of SpikeSemantic proximity Read ↗

Structure of a proteolytically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein.Semantic proximity Read ↗

Inhibition of Viral Membrane Fusion by Peptides and Approaches to Peptide DesignSemantic proximity Read ↗

Peptide derived nanobody inhibits entry of SARS-CoV-2 variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.